Aardvark Adventures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures

DAVE 196.88

+1.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: ~digs who wrote (2758)	3/31/2007 4:47:26 AM
From: ~digs	Read Replies (1) of 7944

VVUS Friday March 30, 12:13 pm ET KV Pharmaceutical Co. said Friday it agreed to buy the U.S. marketing rights to EvaMist, used to alleviate menopause symptoms, from VIVUS Inc. for $150 million -- $10 million at closing plus $140 million once the drug receives final Food and Drug Administration (FDA) approval -- plus additional payments tied to sales. EvaMist is a new estrogen transdermal spray that delivers estradiol for the treatment of vasomotor symptoms, such as hot flashes, associated with menopause. It is expected to be the first transdermal spray estrogen-replacement therapy product approved for use in the U.S., according to a release. EvaMist will be manufactured and supplied to KV Pharmaceutical by a yet unnamed third party. Mountain View, Calif.-based VIVUS Inc. focuses on therapeutic pharmaceutical products addressing obesity and sexual health. biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next